Jun 02, 2020 / 08:00PM GMT
Michael Jonathan Yee - Jefferies LLC, Research Division - Equity Analyst
Hey, everybody. Welcome to a great afternoon session, continuing on the theme here at the 2020 Jefferies Global Healthcare Conference. I'm Michael Yee, Managing Director, as you know. Really excited to have 2 great representatives of Amgen with us here in our virtual fireside. You know them as familiar faces: Arvind Sood, who heads up all of Investor Relations at Amgen; and fresh out of the virtual ASCO, Executive Vice President of R&D, David Reese there.
Before I get into too much specifics, which I'm sure you're all chomping at the bit to have me ask, I wanted to turn it over briefly to Arvin and David. Maybe make some opening comments about Amgen in the state of 2020, given the COVID situation, coming out of the COVID situation, what does it mean for your guidance? And talk about the state of affairs just operationally for Amgen this year.
Arvind Sood - Amgen Inc. - VP of IR
Excellent. Thank you, Mike, and thanks for inviting us to your conference. So I'll just tee up some
Amgen Inc at Jefferies Healthcare Conference (Virtual) Transcript
Jun 03, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers